These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 22315717)

  • 1. The Antibody Response against HIV-1.
    Overbaugh J; Morris L
    Cold Spring Harb Perspect Med; 2012 Jan; 2(1):a007039. PubMed ID: 22315717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
    Braibant M; Barin F
    Retrovirology; 2013 Oct; 10():103. PubMed ID: 24099103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing.
    Datta R; Roy Chowdhury R; Manjunath K; Hanna LE; Varadarajan R
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29584-29594. PubMed ID: 33168755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins.
    Lara HH; Ixtepan-Turrent L; Garza Treviño EN; Singh DK
    J Nanobiotechnology; 2011 Sep; 9():38. PubMed ID: 21923937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive and active antibody studies in primates to inform HIV vaccines.
    Hessell AJ; Malherbe DC; Haigwood NL
    Expert Rev Vaccines; 2018 Feb; 17(2):127-144. PubMed ID: 29307225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
    Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
    Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.
    Lynch JB; Nduati R; Blish CA; Richardson BA; Mabuka JM; Jalalian-Lechak Z; John-Stewart G; Overbaugh J
    J Virol; 2011 Jun; 85(11):5252-61. PubMed ID: 21411521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.
    Haynes BF; Moody MA; Liao HX; Verkoczy L; Tomaras GD
    Trends Mol Med; 2011 Feb; 17(2):108-16. PubMed ID: 21112250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2984-7. PubMed ID: 23602538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.
    Gach JS; Mara KJV; LaBranche CC; van Gils MJ; McCoy LE; Klasse PJ; Montefiori DC; Sanders RW; Moore JP; Forthal DN
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
    Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
    J Virol; 2017 May; 91(9):. PubMed ID: 28202762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.
    Gonzalez-Figueroa P; Roco JA; Vinuesa CG
    Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical question for HIV vaccine development: which antibodies to induce?
    Zolla-Pazner S
    Science; 2014 Jul; 345(6193):167-8. PubMed ID: 25013066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses to envelope glycoproteins in HIV-1 infection.
    Burton DR; Mascola JR
    Nat Immunol; 2015 Jun; 16(6):571-6. PubMed ID: 25988889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?
    Montefiori DC; Mascola JR
    Curr Opin HIV AIDS; 2009 Sep; 4(5):347-51. PubMed ID: 20048696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.